Feeds › 8-K events
8-K events
Major news companies must report to the SEC: results, deals, leadership changes.
About this data
- What it is
- A Form 8-K is how a public company announces major news between its quarterly reports: earnings, an acquisition, a new CEO, a cybersecurity incident. Each filing lists the numbered items it covers.
- Who files it
- The company, usually within four business days of the event.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- Many 8-Ks are routine, so the item description is the place to start. Item 9.01, which only lists attached documents, is hidden unless you ask for it.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
8-K items filed per day, last 30 days
All items Earnings results (2.02)
One filing can report several items. Item 9.01, which only lists attached documents, is not counted.
Latest 8-K filings
Showing: ticker ENGNW
| Filed | Company | Item | Form | Filing |
|---|---|---|---|---|
| Nov 12, 2026 | ENGN enGene Therapeutics Inc. | 8.01 Other Events | 8-K | 8-K ↗ |
| Nov 12, 2026 | ENGN enGene Therapeutics Inc. | 7.01 Regulation FD Disclosure | 8-K | 8-K ↗ |
| Nov 12, 2026 | ENGN enGene Therapeutics Inc. | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Sep 8, 2026 | ENGN enGene Therapeutics Inc. | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Aug 11, 2026 | ENGN enGene Therapeutics Inc. | 8.01 Other Events | 8-K | 8-K ↗ |
| Jul 17, 2026 | ENGN enGene Therapeutics Inc. | 7.01 Regulation FD Disclosure | 8-K | 8-K ↗ |
| Jul 16, 2026 | ENGN enGene Therapeutics Inc. | 7.01 Regulation FD Disclosure | 8-K | 8-K ↗ |
| Jul 16, 2026 | ENGN enGene Therapeutics Inc. | 5.02 Departure or Election of Directors or Officers; Compensatory Arrangements | 8-K | 8-K ↗ |
| Jun 18, 2026 | ENGN enGene Therapeutics Inc. | 5.02 Departure or Election of Directors or Officers; Compensatory Arrangements | 8-K/A | 8-K ↗ |
| Jun 18, 2026 | ENGN enGene Therapeutics Inc. | 2.05 Costs Associated with Exit or Disposal Activities | 8-K/A | 8-K ↗ |
| Jun 15, 2026 | ENGN enGene Therapeutics Inc. | 8.01 Other Events | 8-K | 8-K ↗ |
| Jun 15, 2026 | ENGN enGene Therapeutics Inc. | 7.01 Regulation FD Disclosure | 8-K | 8-K ↗ |
| Jun 15, 2026 | ENGN enGene Therapeutics Inc. | 5.02 Departure or Election of Directors or Officers; Compensatory Arrangements | 8-K | 8-K ↗ |
| Jun 15, 2026 | ENGN enGene Therapeutics Inc. | 2.05 Costs Associated with Exit or Disposal Activities | 8-K | 8-K ↗ |
| Jun 15, 2026 | ENGN enGene Therapeutics Inc. | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Jun 10, 2026 | ENGN enGene Therapeutics Inc. | 5.07 Submission of Matters to a Vote of Security Holders | 8-K | 8-K ↗ |
| May 7, 2026 | ENGN enGene Therapeutics Inc. | 8.01 Other Events | 8-K | 8-K ↗ |
| May 7, 2026 | ENGN enGene Therapeutics Inc. | 7.01 Regulation FD Disclosure | 8-K | 8-K ↗ |
| May 7, 2026 | ENGN enGene Therapeutics Inc. | 5.02 Departure or Election of Directors or Officers; Compensatory Arrangements | 8-K | 8-K ↗ |
| Apr 9, 2026 | ENGN enGene Therapeutics Inc. | 7.01 Regulation FD Disclosure | 8-K | 8-K ↗ |
| Apr 9, 2026 | ENGN enGene Therapeutics Inc. | 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year | 8-K | 8-K ↗ |
| Mar 9, 2026 | ENGN enGene Therapeutics Inc. | 1.02 Termination of a Material Definitive Agreement | 8-K | 8-K ↗ |
| Mar 9, 2026 | ENGN enGene Therapeutics Inc. | 1.01 Entry into a Material Definitive Agreement | 8-K | 8-K ↗ |
| Mar 9, 2026 | ENGN enGene Therapeutics Inc. | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Jan 21, 2026 | ENGN enGene Therapeutics Inc. | 3.02 Unregistered Sales of Equity Securities | 8-K | 8-K ↗ |
| Jan 21, 2026 | ENGN enGene Therapeutics Inc. | 2.03 Creation of a Direct Financial Obligation | 8-K | 8-K ↗ |
| Jan 21, 2026 | ENGN enGene Therapeutics Inc. | 1.01 Entry into a Material Definitive Agreement | 8-K | 8-K ↗ |
| Jan 21, 2026 | ENGN enGene Therapeutics Inc. | 7.01 Regulation FD Disclosure | 8-K | 8-K ↗ |
| Dec 22, 2025 | ENGN enGene Therapeutics Inc. | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Nov 14, 2025 | ENGN enGene Therapeutics Inc. | 7.01 Regulation FD Disclosure | 8-K | 8-K ↗ |
| Nov 14, 2025 | ENGN enGene Therapeutics Inc. | 1.01 Entry into a Material Definitive Agreement | 8-K | 8-K ↗ |
| Nov 12, 2025 | ENGN enGene Therapeutics Inc. | 8.01 Other Events | 8-K | 8-K ↗ |
| Nov 12, 2025 | ENGN enGene Therapeutics Inc. | 7.01 Regulation FD Disclosure | 8-K | 8-K ↗ |
| Oct 2, 2025 | ENGN enGene Therapeutics Inc. | 5.02 Departure or Election of Directors or Officers; Compensatory Arrangements | 8-K | 8-K ↗ |
| Oct 2, 2025 | ENGN enGene Therapeutics Inc. | 5.02 Departure or Election of Directors or Officers; Compensatory Arrangements | 8-K/A | 8-K ↗ |
| Sep 30, 2025 | ENGN enGene Therapeutics Inc. | 7.01 Regulation FD Disclosure | 8-K | 8-K ↗ |
| Sep 11, 2025 | ENGN enGene Therapeutics Inc. | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Sep 3, 2025 | ENGN enGene Therapeutics Inc. | 8.01 Other Events | 8-K | 8-K ↗ |
| Sep 3, 2025 | ENGN enGene Therapeutics Inc. | 7.01 Regulation FD Disclosure | 8-K | 8-K ↗ |
| Jul 8, 2025 | ENGN enGene Therapeutics Inc. | 7.01 Regulation FD Disclosure | 8-K | 8-K ↗ |
| Jul 8, 2025 | ENGN enGene Therapeutics Inc. | 5.02 Departure or Election of Directors or Officers; Compensatory Arrangements | 8-K | 8-K ↗ |
| Jun 12, 2025 | ENGN enGene Therapeutics Inc. | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Jun 10, 2025 | ENGN enGene Therapeutics Inc. | 5.07 Submission of Matters to a Vote of Security Holders | 8-K | 8-K ↗ |
| Jun 10, 2025 | ENGN enGene Therapeutics Inc. | 5.02 Departure or Election of Directors or Officers; Compensatory Arrangements | 8-K | 8-K ↗ |
| Jun 9, 2025 | ENGN enGene Therapeutics Inc. | 2.03 Creation of a Direct Financial Obligation | 8-K | 8-K ↗ |
| Jun 9, 2025 | ENGN enGene Therapeutics Inc. | 1.01 Entry into a Material Definitive Agreement | 8-K | 8-K ↗ |
| Jun 4, 2025 | ENGN enGene Therapeutics Inc. | 7.01 Regulation FD Disclosure | 8-K | 8-K ↗ |
| Jun 4, 2025 | ENGN enGene Therapeutics Inc. | 5.02 Departure or Election of Directors or Officers; Compensatory Arrangements | 8-K | 8-K ↗ |
| Mar 10, 2025 | ENGN enGene Therapeutics Inc. | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Dec 20, 2024 | ENGN enGene Therapeutics Inc. | 1.01 Entry into a Material Definitive Agreement | 8-K | 8-K ↗ |
The newest 50 items, most recent first. Every row links to its original filing. Updated Nov 15, 2026, 6:22 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances